[Forbes Korea] CEO JaeMin Park of Thyroscope Inc. Named Among Y30s RISING AI LEADERS

The latest scientific and technological achievements of student startups based at UNIST have garnered international acclaim.

Thyroscope Inc. (CEO JaeMin Park), a university-led venture company, has pioneered the world’s first commercialization of an AI-powered medical device for thyroid disease. Its flagship product, Glandy, is an AI medical device designed to assist with chronic thyroid conditions and associated complications. Notably, Glandy enables patients in underserved regions to assess their condition in daily life and transmit data directly to healthcare providers, facilitating personalized treatment options.

Building on a solid foundation of over 120 domestic and international patents and the publication of 10 SCI-level research papers, Thyroscope has made a remarkable entry into the global digital healthcare arena. The company has attracted over KRW 10 billion in cumulative investment and is the first Korean AI medical company to pursue FDA De Novo approval in the United States. Additionally, it has completed pre-consultations for approval with Japan’s PMDA. Currently conducting clinical trials in ten countries, Thyroscope is validating its device across diverse populations.

CEO JaeMin Park, a graduate of UNIST’s programs in business administration and computer engineering, also holds a master’s degree in Industrial Engineering with a focus on anomaly detection. He is the founder of the company. His research-driven background led him to focus on thyroid diseases—conditions affecting 6% of the population but often overlooked by industry. In the traditional field, where only low-cost generic drugs remain after patent expirations, he sought innovative solutions.

Developing the world’s first medical device was no easy feat. With no precedents to follow, every aspect—from clinical trial design to regulatory approval—had to be devised from scratch. Collaborating with global researchers met through academic conferences, Thyroscope is now building momentum through international joint research and clinical achievements.

“I believe in taking calculated risks. I want to dream, create, fail, and succeed again,” says CEO JaeMin Park.

His entrepreneurial philosophy is inspired by Thomas Paine’s words that is “The entrepreneur is someone who calmly calculates the risks involved in every decision and perseveres through them.” For Park, entrepreneurship means embracing risks with a measured attitude and relentless determination.

He emphasizes, “Great medical devices can elevate healthcare standards across the board. Our goal at Thyroscope is to leverage digital and AI technology to help patients worldwide receive better diagnosis and treatment for thyroid diseases.”

《Editor’s Note: This article is based on an interview with CEO JaeMin Park of Thyroscope Inc., originally published in Forbes Korea on September 29, 2025, under the title “[Y30s RISING AI LEADERS] CEO JaeMin Park of Thyroscope Inc.”》